|
Serum phospholipids fatty acids and breast cancer risk by pathological subtype: EpiGEICAM study. |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; Novartis |
Speakers' Bureau - AstraZeneca; Novartis; Pfizer; Roche |
Research Funding - Pfizer (Inst) |
Travel, Accommodations, Expenses - Novartis; Pfizer; Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Genentech; Novartis |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Bayer |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - Lilly |
Speakers' Bureau - Roche; Roche |
Travel, Accommodations, Expenses - Lilly; Roche; Roche |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Consulting or Advisory Role - AstraZeneca; Lilly; Novartis; Pfizer; PharmaMar; Roche/Genentech; Taiho Pharmaceutical |
Research Funding - Novartis (Inst); Roche (Inst) |
| |
|
No Relationships to Disclose |